Navigation Links
Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease

• Data presented at Movement Disorder Society’s 11th International Congress
• Management of cognitive impairment in early Parkinson’s disease patients is a critical unmet medical need

Geneva, Switzerland, June 8, 2007 – Merck Serono S.A. (virt-x: SEO) and its partner Newron Pharmaceuticals S.p.a. (SWX: NWRN) announced today data, which suggest that safinamide, a new agent in Phase III development for the treatment of Parkinson’s disease, has an effect on cognitive performance in study patients with early Parkinson’s disease. These data were presented yesterday in a poster session at the Movement Disorder Society’s 11th International Congress in Istanbul, Turkey.

The data are from a 6-month (24 weeks), randomized, double blind, placebo-controlled, international Phase III trial. Some results from this trial were presented last month at the American Academy of Neurology 59th Annual Meeting and showed that safinamide significantly improved motor symptoms and activities of daily living for patients in the trial, as an add-on treatment to dopamine agonist therapy1. The cognition testing was carried out in an exploratory manner in selected centers, which agreed to conduct this part of the trial.

“Parkinson’s disease affects several cognitive functions even at an early stage of the disease”, said Professor Anthony Schapira, chairman of the University Department of Clinical Neuroscience, Royal Free and University College London Medical School, and an investigator of the study. "These study results suggest that safinamide may have an effect on cognitive performance in patients with early Parkinson’s disease, and has the potential to address a critical unmet medical need”.

The data demonstrated that the addition of safinamide to a stable dose of a single dopamine agonist in study patients with early stage Parkinson’s disease resulted in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
8. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
9. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
10. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
11. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
Post Your Comments:
(Date:8/27/2008)...ionally Recognized Pediatric Heart Center at The C...s for Community to Complete Range of Care and ...Recruited Pediatric Cardiology Team Treats Every H...ewswire/ -- The Children,s Hospital at,Montefiore ...c heart,transplantation to the Bronx, following th...
(Date:8/26/2008)...SALEM, Ore., Aug. 26 /- The Oregon To...ity Care Customer Service Training Program,(Q Care...gon Q Care is a training program created to suppor...anced employee education. By emphasizing,the impor...ll equip,employees with tools and resources to bet...
(Date:8/26/2008)...INDIANAPOLIS, Aug. 26 /- Semafore Pha...Seventh International Congress on Targeted,Therapi...al antiangiogenic,activity of vascular-targeted PI... VEGF and Bv8 signaling., PI3K is part of a very ...as been shown to play a major role in cancer. Stud...
(Date:8/26/2008)...Study finds most patients can drive safely six wee...Aug. 26 /PRNewswire-USNewswire/ -- Six weeks follo...e so low that they are able to,get back behind the...gust,2008 issue of The Journal of Bone and Joint S...ergency brake time response in patients who underw...
Breaking Medicine Technology:Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Oregon Tourism Commission Unveils New Online Customer Service Training Program 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Braking After Bunion Surgery 2Braking After Bunion Surgery 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 1Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2601 5MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 1MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 2MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files 241 6 Billion Court Claim against AECL and the Government of Canada 23553 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 1CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 6439 4Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 1Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 23549 2
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ty Massey Cancer Center have discovered a process ...cules containing platinum, which causes HIV and ca...the researchers to develop new drugs to fight HIV ...argeting proteins known as zinc fingers. In the M...
...at funds for wheelchair service from NHS has not r...ildren are losing out their hope due to lack of a ...wheelchair with most basic parts, was given due to...sh Me Around!’, highlights. Thus it calls for Gove...
...n (NBA) have entered into a partnership to support.... // The campaign, 'Unite for Children, Unite aga.../AIDS on children as well as impeding further spre...e know that our sport, indeed all sports, has an e...
...hetamine-like stimulant has a calming effect on ch...er (ADHD) // . A new study undertaken on rats, se...ly used to treat ADHD, appears to work by tweaking...acted by any stimuli from the outside world. The s...
Other Medicine News:Health News:New Research May Be Useful for Developing Drugs for HIV and Cancer 2Health News:Ritalin Could Help In Focussing The Mind 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: